Global oncology drugs market expected to reach over USD 530 billion by 2032

From GlobeNewswire: 2025-03-17 10:00:00

The global Oncology Drugs Market was valued at USD 202.30 billion in 2023, expected to reach USD 530.39 billion by 2032, with a CAGR of 11.34%. Advancements in targeted therapies and rising cancer cases are driving growth. Companies like Roche, Novartis, Pfizer, and AstraZeneca are leading the market with innovative products.

Targeted therapies dominate the market, offering selective cancer cell targeting. Immunotherapies show promise for long-term survival. Breast cancer treatments are advancing rapidly, with AstraZeneca’s Camizestrant showing encouraging results in late-stage trials. Sun Pharma’s acquisition of Checkpoint Therapeutics boosts oncology portfolio. FDA approved Datroway for advanced breast cancer treatment.

In 2023, Injectable dosage forms led the market, with hospital pharmacies as the primary distribution channel. Online pharmacies are expected to grow rapidly. Market segmentation by drug class, therapy, indication, dosage form, and distribution channel provides insight into the evolving landscape of oncology drug treatments. Pharmaceutical companies are investing heavily in research and development to bring innovative therapies to the market. In 2023, there were 20.1 million new cancer cases globally, with lung, breast, and colorectal cancers leading. North America saw over 40% of oncology prescriptions due to healthcare infrastructure, while the Asia-Pacific region saw rising prescription rates. By 2032, the Asia-Pacific oncology drug market is expected to show the highest volume growth.

Immunotherapies are predicted to make up 30% of total oncology drug sales by 2032, with the development of combination regimens reshaping cancer therapy strategies. Around 50% of oncology drug spending in North America is government-funded, while out-of-pocket spending in developing countries affects patient affordability of new drugs.



Read more at GlobeNewswire: Oncology Drugs Market Size to Surpass USD 530.39 Billion by